145 related articles for article (PubMed ID: 24799957)
1. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.
Sato Y; Kondo M; Inagaki A; Komatsu H; Okada C; Naruse K; Sahashi T; Kuroda J; Ogura H; Uegaki S; Yoshida T; Mori Y; Sawada H; Watanabe S; Sugiura H; Endo Y; Yoshimoto N; Toyama T; Iida S; Yamada K; Kimura K; Wakita A
J Cancer; 2014; 5(5):390-7. PubMed ID: 24799957
[TBL] [Abstract][Full Text] [Related]
2. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy.
Hegerova LT; Leal AD; Grendahl DC; Seisler DK; Sorgatz KM; Anderson KJ; Hilger CR; Loprinzi CL
Support Care Cancer; 2015 Jan; 23(1):55-9. PubMed ID: 24964876
[TBL] [Abstract][Full Text] [Related]
3. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Boccia R; Geller RB; Clendeninn N; Ottoboni T
Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
[TBL] [Abstract][Full Text] [Related]
7. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
Leal AD; Kadakia KC; Looker S; Hilger C; Sorgatz K; Anderson K; Jacobson A; Grendahl D; Seisler D; Hobday T; Loprinzi CL
Support Care Cancer; 2014 May; 22(5):1313-7. PubMed ID: 24402411
[TBL] [Abstract][Full Text] [Related]
8. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.
Edwards JK; Bossaer JB; Lewis PO; Sant A
J Oncol Pharm Pract; 2020 Jun; 26(4):809-813. PubMed ID: 31446866
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Olver IN
Ther Clin Risk Manag; 2008 Apr; 4(2):501-6. PubMed ID: 18728837
[TBL] [Abstract][Full Text] [Related]
11. Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
Yamasaki M; Kimura R; Mayahara S; Maeda Y; Takahashi M; Nishida T; Oda K; Murakami T
Mol Clin Oncol; 2019 Jul; 11(1):43-49. PubMed ID: 31289676
[TBL] [Abstract][Full Text] [Related]
12. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
[TBL] [Abstract][Full Text] [Related]
13. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.
Celio L; Ricchini F; De Braud F
Patient Prefer Adherence; 2013; 7():391-400. PubMed ID: 23687442
[TBL] [Abstract][Full Text] [Related]
15. [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
Uchiyama K; Yamada M; Shiiba Y; Kasazaki S; Suga K; Iwabuchi H; Asoda S; Uehara K
Gan To Kagaku Ryoho; 2017 Jul; 44(7):585-589. PubMed ID: 28790262
[TBL] [Abstract][Full Text] [Related]
16. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Ando Y; Hayashi T; Ito K; Suzuki E; Mine N; Miyamoto A; Oya M; Matsuda H; Isaji A; Nakanishi T; Imaizumi K; Shibata T; Okada T; Sakurai K; Naito K; Uyama I; Kawada K; Takahashi H; Yamada S
Support Care Cancer; 2016 Feb; 24(2):871-878. PubMed ID: 26206077
[TBL] [Abstract][Full Text] [Related]
17. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
[TBL] [Abstract][Full Text] [Related]
20. Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives.
Candelario N; Lu ML
Cancer Manag Res; 2016; 8():77-82. PubMed ID: 27382332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
